Results 251 to 260 of about 133,829 (277)

Increased RANK ligand in bone marrow of orchiectomized rats and prevention of their bone loss by the RANK ligand inhibitor osteoprotegerin

Bone, 2009
Orchiectomized (ORX) rats were used to examine the extent to which their increased bone resorption and decreased bone density might relate to increases in RANKL, an essential cytokine for bone resorption.
Xiaodong, Li, Michael S, Ominsky, Marina, Stolina, Kelly S, Warmington, Zhaopo, Geng, Qing-Tian, Niu, Frank J, Asuncion, Hong-Lin, Tan, Mario, Grisanti, Denise, Dwyer, Steven, Adamu, Hua Zhu, Ke, W Scott, Simonet, Paul J, Kostenuik   +13 more
openaire   +2 more sources

New actions of rank ligand

Bone, 2012
increased fracture risk occur early after therapy is initiated, emphasising the importance of primary prevention of fracture in high-risk individuals. Most currently available guidelines for the management of GIO were developed prior to the release of FRAX® and other risk assessment tools and the approval of newer pharmacological interventions for its ...
openaire   +1 more source

Detection and characterization of RANK ligand and osteoprotegerin in the thyroid gland

Journal of Cellular Biochemistry, 2002
AbstractReceptor activator of NF‐κB (RANK) ligand (RANKL) and osteoprotegerin (OPG) play essential roles in bone metabolism and immune responses. RANKL activates RANK, which is expressed by osteoclasts and dendritic cells (DC), whereas OPG acts as its decoy receptor. The role of RANKL and OPG in thyroid physiology is unclear. Northern analysis revealed
Lorenz C, Hofbauer, Sibylle, Kluger, Christian A, Kühne, Colin R, Dunstan, Andreas, Burchert, Michael, Schoppet, Andreas, Zielke, Armin E, Heufelder   +7 more
openaire   +2 more sources

RANK ligand is a prerequisite for cancer‐associated osteolytic lesions

The Journal of Pathology, 2002
AbstractBreast cancer is frequently associated with osteolytic bone metastasis, where osteoclasts play a major role in bone destruction. Recently, osteoclast differentiation factor (RANKL) has been identified as a prerequisite for the formation and maintenance of osteoclasts from haematopoietic precursors.
Sohei, Kitazawa, Riko, Kitazawa
openaire   +2 more sources

Osteonecrosis of the jaws induced by anti-RANK ligand therapy

British Journal of Oral and Maxillofacial Surgery, 2010
Since the introduction of bisphosphonates to treat diseases that affect remodelling of bone, increasing numbers of patients with bisphosphonate-related osteonecrosis of the jaws have been reported; the number is currently unknown. Recently anti-RANKL agents (receptor activator of nuclear factor-kappaB ligand) such as denosumab (Prolia, Amgen Inc ...
K H, Taylor, L S, Middlefell, K D, Mizen
openaire   +2 more sources

TNF‐α expression is transcriptionally regulated by RANK ligand

Journal of Cellular Physiology, 2004
AbstractTumor necrosis factor (TNF)‐α is known for its osteoclastogenic and resorptive activities. Induction of osteoclastogenesis by receptor activator of NF‐κB ligand (RANKL) is accompanied by increased TNF‐α expression. In the present study we investigated the mechanism by which RANKL induces expression of TNF‐α in osteoclast precursors.
W, Zou, A, Amcheslavsky, S, Takeshita, H, Drissi, Z, Bar-Shavit   +4 more
openaire   +2 more sources

Using motion planning to rank ligand binding affinity

Proceedings of the 6th ACM Conference on Bioinformatics, Computational Biology and Health Informatics, 2015
In the drug discovery process, pharmaceutical companies have to screen many drug (or ligand) candidates to find the most promising ones for trial. This process is very costly and attention as turned to computational approaches to predict binding affinity to the desired target protein.
Hsin-Yi Cindy Yeh, Shawna L. Thomas, Nancy M. Amato   +2 more
openaire   +1 more source

Denosumab, a RANK Ligand Inhibitor, for Postmenopausal Women with Osteoporosis

Annals of Pharmacotherapy, 2012
OBJECTIVE: To review the evidence for use of denosumab for the treatment of postmenopausal osteoporosis. DATA SOURCES: A search of MEDLINE and EMBASE databases was conducted during January 2012, using the terms denosumab and ...
Emily E, Sutton, Daniel M, Riche
openaire   +2 more sources

Crystal Structure of RANK Ligand Involved in Bone Metabolism

2004
Bone remodeling involves the resorption of bone by osteoclasts and the synthesis of bone matrix by osteoblasts. Recently, an essential cytokine system for osteoclast biology has been identified and extensively characterized. This system consists of a ligand, receptor activator of NF-kappaB ligand (RANKL), a receptor, RANK, and its soluble decoy ...
Shuichiro, Ito, Tadashi, Hata
openaire   +2 more sources

[Inhibition of RANK ligand to treat bone metastases].

Bulletin du cancer, 2013
info:eu-repo/semantics ...
openaire   +2 more sources